Ischemic and Bleeding Outcomes of Potent P2Y12 Inhibitor Antiplatelet Agents Versus Clopidogrel in Elderly Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials

Abusnina, Waiel; Al‐Abdouh, Ahmad; Bizanti, Anas; Gill, Gauravpal S.; Houssien, Abdelrazeg; Alshebani, Yazeid; Kanmanthareddy, Arun; Dahal, Khagendra

doi:10.1016/j.carrev.2021.08.008

Cited by 3 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could potentially be explained by the reversible inhibition provoked by ticagrelor compared to the irreversible inhibition of prasugrel or clopidogrel, which might be of importance in cases of severe bleeding. As far as special patient populations are concerned, patients with chronic kidney disease may benefit from the use of prasugrel [ 136 ], while the use of the novel, potent P2Y 12 inhibitors may reduce the risk of ischemic events at the expense of excess bleeding in the elderly [ 137 ]. Intriguingly, a recent meta-analysis demonstrated the key role of the CYP2C19 loss-of-function, as it was a critical moderator of the difference in efficacy between clopidogrel and ticagrelor/prasugrel [ 138 ].…”

Section: Therapeutic Approachesmentioning

confidence: 99%

Factors Associated with Platelet Activation-Recent Pharmaceutical Approaches

Theofilis

Sagris

Oikonomou

et al. 2022

IJMS

View full text Add to dashboard Cite

Platelets are at the forefront of human health and disease following the advances in their research presented in past decades. Platelet activation, their most crucial function, although beneficial in the case of vascular injury, may represent the initial step for thrombotic complications characterizing various pathologic states, primarily atherosclerotic cardiovascular diseases. In this review, we initially summarize the structural and functional characteristics of platelets. Next, we focus on the process of platelet activation and its associated factors, indicating the potential molecular mechanisms involving inflammation, endothelial dysfunction, and miRs. Finally, an overview of the available antiplatelet agents is being portrayed, together with agents possessing off-set platelet-inhibitory actions, while an extensive presentation of drugs under investigation is being given.

show abstract

Section: Therapeutic Approachesmentioning

confidence: 99%